Novartis is preparing to file for approval of its radioligand therapy Lutathera as a first-line treatment for people with rare neuroendocrine tumours after it showed a benefit in a phase 3 trial.

Novartis currently markets Lutathera (lutetium Lu 177 dotatate), an approved peptide receptor radionuclide therapy (PRRT) for SSTR-positive GEP-NETs. Sanofi has also entered the space, having ...

Novartis Oncology. "With Lutathera we can build on this legacy by expanding the global reach of this novel, differentiated treatment approach and work to maximise Advanced Accelerator Applications ...

Last year, Novartis agreed to buy U.S.-based Mariana Oncology for $1 billion upfront to expand its portfolio of the drugs, which currently include prostate cancer treatment Pluvicto and Lutathera used ...

Lutathera, won European Union backing in late September for use against gastroenteropancreatic neuroendocrine tumours, the kind of cancer that killed Apple founder Steve Jobs. “Novartis has a ...

Swiss pharmaceutical giant Novartis (SIX:NOVN) is keeping a close eye on the U.S. tariff policy proposed by the Biden ...